Xickle® RBC-Plus™ is available now. WHY WAIT. Live a Healthier Life!
Connect With Us

Another Milestone in Our Quest for FDA Approval

March 9, 2015 by Andrea

Stethoscope 3
Just three months in and already 2015 has been off to a good start for Xickle. In January, we announced plans for a clinical trial; in February, we published a brief preview of our research; and this month, we've not only been a part of an amazing sickle cell-centric radio show, but now, we're excited to share that our clinical trial has officially been published on clinicaltrials.gov

To summarize, our clinical trial is studying the safety and clinical effects of SCD-101 (the drug equivalent of Xickle RBC-Plus) in adults with sickle cell disease. Effectively identical to Xickle RBC-Plus -- it's made in the same plant, by the same process, and bottled by the same company -- SCD-101 "inhibits sickling of red blood cells containing Hb S (sickle hemoglobin) under low oxygen conditions ... SCD-101 may inhibit red blood cell sickling in patients with sickle cell disease and reduce symptoms and slow disease progression." 

We believe so strongly in our product and have seen how it has positively affected our current users, so this trial is quite significant since it's bringing us one step closer to FDA approval, ultimately giving us solid credibility as a treatment for SCD. While we work through the approval process (which can take 4-6 years), we will continue to offer Xickle RBC-Plus as a supplement via our website.

To learn even more about our current clinical trial, including criteria, outcome measures, and important dates, read more here -- and of course, spread the word! 

Are you excited about this clinical trial? Have any questions? Tell us in the comments below!


Sign Up For Xickle's Newsletter!

Get the latest news, health tips and special offers!








Click to access the login or register cheese
Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!